CN Bio and LifeNet Health LifeSciences Partner to Supply Validated Human Primary Cells for Microphysiological Systems

CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single- and multi-organ microphysiological systems (MPS), and LifeNet Health LifeSciences, a global non-profit leader. LifeNet Health All-Human Research Solutions today announced a strategic partnership to supply validated primary human cells for use in CN Bio’s MPS PhysioMimix® OOC series. Under this agreement, LifeNet Health’s high-quality, MPS-validated hepatocytes will be available in CN Bio’s non-alcoholic steatohepatitis (NASH) ‘in-a-box’ kits or directly from LifeNet Health, Provide customers with efficient solutions. Reproduce our advanced in vitro liver models to maximize assay success.

Lot validation in standard static 2D or 3D cell cultures does not guarantee performance of primary cells in perfused MPS cultures. An analysis performed by CN Bio over his five years demonstrated that >60% of hepatocyte lots from various suppliers did not meet acceptable performance criteria for his MPS assay. Therefore, cell lots used in MPS assays should be pre-validated to ensure the generation of robust and reliable human-relevant data. The validation process itself requires users to consider additional resources, time, and budget to prove cell stability prior to use.

CN Bio and LifeNet Health have joined forces to provide PhysioMimix customers with “off-the-shelf” access to well-characterized and MPS-validated hepatocytes that facilitate the delivery of reliable and reproducible results. signed a partnership. The partnership is aimed at reducing the need for researchers to conduct resource-intensive validation studies, minimizing the risk of experimental failures and increasing workflow efficiencies. Through this partnership, customers will further benefit from Lifenet Health’s reputation for providing high-quality cells, large-lot access, donor diversity, and more complete donor medical and genetic information. Masu.

Under the new contract, CN Bio will use a rigorous process to grow selected hepatocytes, astrocytes and Kupffer cells that have been grown in expanded 3D MPS cultures and proven to maintain function and phenotype for at least two weeks We plan to pre-qualify the cells. To support a variety of research requirements, hepatocytes can be purchased through CN Bio’s 3D validated cell portfolio and his NASH-in-a-box kits or directly from LifeNet Heath.

CN Bio Chief Scientific Officer Tomasz Kostrzewski, Ph.D.

LifeNet Health and CN Bio share a commitment to helping researchers bring safer, more effective treatments to patients faster, without unnecessary animal testing. “

he added:

In our studies, LifeNet Health’s cells have shown consistently high success rates, and we believe this will lead to more reliable and reproducible results. Our partnership is an important milestone for existing customers as well as customers looking to bring OOC technology into their labs. Validation of cells is an expensive and laborious process, but it is essential for a successful assay. By leveraging our combined technical expertise and customer support, we are able to easily replicate industry-leading liver models and provide researchers with a more complete solution to eliminate risk. Avoid experiment failures caused by untested cells or the burden of in-house QC testing, allowing you to focus your efforts on new discoveries. “

Dr. Ed LeCluyse, Principal Investigator at LifeNet Health LifeSciences, said:

The partnership represents a joint investment to set a new standard for cell quality across the industry, enabling customers across a wide range of market segments to realize the potential of OOC without the need for costly in-house validation You will be able to “

he added:

Our cells are fully characterized for quality and performance to ensure they function within advanced platforms and more effectively mimic in vivo biology. “

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *